
		• Screening for hepatitis C in adults: recommendation statement. United States Preventive Services Task Force. • 2002 national guideline on the management of the viral hepatitides A, B, and C. AGUM, MSSVD. • Hepatitis A virus. New York State Department of Health. • Screening for hepatitis B virus infection: recommendation statement. U.S. Preventive Services Task Force (USPSTF). • Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. • Hepatitis B virus. New York State Department of Health.


		• Alcoholic Hepatitis • Cutaneous Manifestations of Hepatitis C • Hepatitis A • Hepatitis C • View All Hepatitis Articles


		• Cutaneous manifestations of hepatitis C. Erythema dyschromicum perstans. • Cutaneous manifestations of hepatitis C. Lichen planus. • Diagnostic algorithm for hepatitis C. • Hepatitis B. Ground-glass appearance of hepatocytes. • Hepatitis B. Liver biopsy. Stage 3 fibrosis. • View All Hepatitis Multimedia Files


		• Foreign Travel • Hepatitis A • Hepatitis B • Hepatitis C • Immunization Schedule, Adults • Immunization Schedule, Children • Sexually Transmitted Diseases


		• Acid-base disturbance graph • Ibuprofen toxicity nomogram • Salicylate toxicity nomogram • Sodium Deficit In Hyponatremic Females • Sodium Deficit In Hyponatremic Males • Sodium Excess In Hypernatremic Females • Sodium Excess In Hypernatremic Males

Hepatitis Resource Center

The prevalence of hepatitis C virus (HCV) infection is increasing worldwide. The World Health Organization estimates that more than 170 million individuals throughout the world are infected with HCV. An estimated 1.8% of the population in the United States is positive for HCV antibodies; this rate corresponds to an estimated 3.9 million persons with HCV infection nationwide. Infection due to HCV accounts for 20% of all cases of acute hepatitis, an estimated 30,000 new acute infections, and 8,000-10,000 deaths each year in the United States. Most patients infected with HCV have chronic liver disease, which may progress to cirrhosis and hepatocellular carcinoma. Chronic infection with HCV is one of the most important causes of chronic liver disease.

Hepatitis C

Gastroenterology

Hepatitis C Feature Series Newsletters

Recommendations on Newborn Screening for Hepatitis C Virus Infection
(Series 2, Issue 12)

Cutaneous Manifestations of Hepatitis C

Get 1.5 AMA PRA Category 1 Credits^TM by completing this peer-reviewed online course from eMedicine's Clinical Knowledge Base. Learn the latest point-of-care management of chronic hepatitis C, which can involve the dermatologic, neurologic, gastrointestinal, and musculoskeletal systems, in this comprehensive review course.

Hepatitis B

Get 1.5 AMA PRA Category 1 Credits^TM by completing this peer-reviewed online course from eMedicine's Clinical Knowledge Base. In this comprehensive clinical review, learn the latest point-of-care management of this disease that can range in presentation from an asymptomatic chronic carrier state to severe, end-stage, chronic hepatitis, which may necessitate a liver transplant.

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

This double blind phase followed by open label phase clinical trial assessed whether epoetin alfa could maintain ribavirin dose, that is to ameliorate its anemia causing effects when used in the treatment of hepatitis C. The findings of this study showed that Epoetin alfa maintained ribavirin dose and improved quality of life and hemoglobin in anemic HCV-infected patients receiving combination therapy.

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial.

This is a randomized controlled trial that evaluated whether short-term therapy with interferon (IFN) during acute hepatitis C is effective in preventing the development of chronic hepatitis. Results showed that short-term (4 weeks) IFN treatment of patients with acute hepatitis C may be associated with satisfactory results, if initiated at an early stage of the disease.

Treatment of chronic hepatitis C in HIV/HCV - coinfection with interferonTreatment of chronic hepatitis C in HIV/HCV - coinfection with interferon alpha-2b+ full-course versus 16-week delayed ribavirin.

This randomized trial of 107 patients coinfected with HIV and HCV to receive interferon alfa-2b (IFN) plus either a full course of ribavirin (RBV) or 16 weeks of placebo, followed by RBV. Results showed that HCV therapy with IFN plus RBV is relatively safe in patients coinfected with HIV and HCV, but frequent treatment discontinuations and anemia-related RBV dose reductions contribute to a poor sustained viral response rate. Control of HIV infection improves rather than worsens during therapy.

Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation. 2004 Apr 28;77(8):1203-1208.

Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol. 2004 May;78(10):5170-83.

Dreier J, Kroger M, Diekmann J, Gotting C, Kleesiek K. Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med. 2004 Apr;14(2):97-103.

Bruno CM, Neri S, Sciacca C, Bertino G, Di-Prima P, Cilio D, et al. Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases. World J Gastroenterol 2004 May 1;10(9):1353-6.

Lessells R, Leen C. Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis. 2004 May;23(5):366-74.

We subscribe to the
HONcode principles of the
Health On the Net Foundation

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.